A growing understanding of the multiple genetic and environmental pathways that contribute to the development of cancer is leading to the concept of a personalized approach to cancer therapy and prevention. This requires techniques to characterize patient and tumor factors that will drive specific targeted interventions and measure their effectiveness. Biomedical imaging now offers the opportunity to characterize tumor anatomy, physiology, and molecular biology in unprecedented ways. The challenge is to harness this technology to develop quantitative approaches to diagnosis that will support the development and application of targeted treatments and preventive interventions. Since its inception, ACRIN has developed and implemented multicenter clinical trials to establish the effectiveness of imaging in the detection, characterization and monitoring of cancer. Working with its biostatistics center at Brown University, ACRIN has assembled a unique organization of hundreds of clinical imaging specialists, other clinicians, and non-physician researchers at more than a hundred institutions nationally and internationally working collaboratively with the broader cancer research community dedicated to cancer imaging research. Over the next grant cycle, ACRIN proposes 3 major scientific objective related to the theme of personalized cancer care: 1. targeted surveillance of at-risk populations;2.characterization of cancer in order to drive targeted therapy;and 3. development of imaging-based predictive and prognostic biomarkers of response to targeted treatment. Through its continued leadership in the imaging community, ACRIN will play a pivotal role in the advancement of cancer detection and therapy. ACRIN will work to discover ways for imaging to improve cancer care. This includes determining the optimal methods to detect cancer early in order to provide the best opportunity for cure, and establishing techniques to characterize cancer and its response to treatment in order to choose the most appropriate therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA080098-14S2
Application #
8528753
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (O1))
Program Officer
Henderson, Lori A
Project Start
1999-03-06
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2014-12-31
Support Year
14
Fiscal Year
2013
Total Cost
$5,146,722
Indirect Cost
$1,226,114
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Cureton, Elizabeth L; Yau, Christina; Alvarado, Michael D et al. (2014) Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 21:2889-96
National Lung Screening Trial Research Team; Church, Timothy R; Black, William C et al. (2013) Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 368:1980-91
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Lin, Cheryl; Buxton, Meredith Becker; Moore, Dan et al. (2012) Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat 132:871-9
Esserman, Laura J; Berry, Donald A; Cheang, Maggie C U et al. (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132:1049-62
Berg, Wendie A; Zhang, Zheng; Lehrer, Daniel et al. (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394-404